Compare Etsy Inc (ETSY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Incyte Corporation — how do they compare? Etsy Inc trades at $85.51 (market cap $8.14B), while Incyte Corporation trades at $115 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 2.8× Etsy Inc's market cap. Which is the better fit depends on your goals.
| ETSY | INCY | |
|---|---|---|
Market Cap | $8.14B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $118.52 |
52-Week Low | $44.05 | $67.38 |
Enterprise Value | $9.79B | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $84.30, up 1.49% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats in recent quarters but faces declining revenue and net income margins year-over-year. Positive sentiment is driven by AI-powered seller tools and app engagement growth, though active buyer declines remain a concern. Cash flow improved significantly in 2025 to $593 million.
Outlook is mixed: analyst consensus is cautious with a $72.38 price target below current levels, but technical momentum and AI initiatives offer upside potential. Key risks include high debt, competitive pressure, and inconsistent profitability. Institutional sentiment leans bullish with 49% buy ratings.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
